BridgeBio Pharma (BBIO)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.09 (+0.35%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of BridgeBio Pharma (BBIO)
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Key Insights

Critical company metrics and information

  • Share Price

    $27.10

  • Market Cap

    $5.12 Billion

  • Total Outstanding Shares

    188.99 Million Shares

  • Total Employees

    556

  • Dividend

    No dividend

  • IPO Date

    June 27, 2019

  • SIC Description

    Pharmaceutical Preparations

  • Homepage

    https://www.bridgebio.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Investing Activities, Continuing$63.95 Million
Net Cash Flow From Operating Activities, Continuing$-450.22 Million
Net Cash Flow From Operating Activities$-450.22 Million
Net Cash Flow From Financing Activities$270.00 Million
Net Cash Flow, Continuing$-116.26 Million
Net Cash Flow From Investing Activities$63.95 Million
Net Cash Flow From Financing Activities, Continuing$270.00 Million
Net Cash Flow$-116.26 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Diluted Average Shares$188.85 Million
Basic Average Shares$188.85 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Income/Loss From Continuing Operations After Tax$-446.29 Million
Costs And Expenses$762.13 Million
Basic Earnings Per Share$2.42
Preferred Stock Dividends And Other Adjustments$0.00
Income/Loss From Continuing Operations Before Tax$-446.29 Million
Diluted Earnings Per Share$2.42
Net Income/Loss Attributable To Noncontrolling Interest$-7.43 Million
Net Income/Loss$-446.29 Million
Selling, General, and Administrative Expenses$241.73 Million
Net Income/Loss Attributable To Parent$-438.86 Million
Cost Of Revenue$2.39 Million
Other Operating Expenses$7.57 Million
Gross Profit$215.37 Million
Operating Income/Loss$-544.36 Million
Nonoperating Income/Loss$98.08 Million
Benefits Costs and Expenses$664.05 Million
Operating Expenses$759.74 Million
Research and Development$506.34 Million
Net Income/Loss Available To Common Stockholders, Basic$-438.86 Million
Revenues$217.76 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Liabilities$1.88 Billion
Wages$43.54 Million
Current Liabilities$139.22 Million
Noncurrent Assets$220.40 Million
Assets$664.98 Million
Current Assets$444.58 Million
Liabilities And Equity$664.98 Million
Other Non-current Assets$187.17 Million
Other Current Liabilities$82.31 Million
Equity$-1.22 Billion
Equity Attributable To Noncontrolling Interest$10.88 Million
Accounts Payable$13.36 Million
Noncurrent Liabilities$1.74 Billion
Fixed Assets$8.70 Million
Equity Attributable To Parent$-1.23 Billion
Intangible Assets$24.52 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
Earnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

ⓒ 2024 Financhle. All Rights Reserved.